[
  {
    "ts": null,
    "headline": "Regeneron and Tessera join forces to forge in vivo AATD gene therapy",
    "summary": "If approved, TSRA-196 could become the first curative therapy to reach patients with AATD.",
    "url": "https://finnhub.io/api/news?id=53dc71f8b468b0e2d9abf3a1dd7f1098fccf553f34683fa0d664c1ba6246fc5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764611399,
      "headline": "Regeneron and Tessera join forces to forge in vivo AATD gene therapy",
      "id": 137654758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "If approved, TSRA-196 could become the first curative therapy to reach patients with AATD.",
      "url": "https://finnhub.io/api/news?id=53dc71f8b468b0e2d9abf3a1dd7f1098fccf553f34683fa0d664c1ba6246fc5f"
    }
  },
  {
    "ts": null,
    "headline": "European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension",
    "summary": "Key market opportunities include. Companies like Novo Nordisk, Regeneron, AstraZeneca, and Vertex are leading innovation, presenting new avenues for treatment in metabolic and cardiovascular conditions.Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The \"European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights\" report has been added to ResearchAndMarkets.com's offering.The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization",
    "url": "https://finnhub.io/api/news?id=d40437b9a8e3c49aa8b2e79c85e0f3ad8a078d5d047693bf8a58bc0f7fa28f06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764605400,
      "headline": "European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension",
      "id": 137654759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Key market opportunities include. Companies like Novo Nordisk, Regeneron, AstraZeneca, and Vertex are leading innovation, presenting new avenues for treatment in metabolic and cardiovascular conditions.Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The \"European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights\" report has been added to ResearchAndMarkets.com's offering.The European Association for the Study of Diabetes (EASD) is a leading academic, non-profit organization",
      "url": "https://finnhub.io/api/news?id=d40437b9a8e3c49aa8b2e79c85e0f3ad8a078d5d047693bf8a58bc0f7fa28f06"
    }
  },
  {
    "ts": null,
    "headline": "REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?",
    "summary": "Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.",
    "url": "https://finnhub.io/api/news?id=047431453b74569e2c937bb7b42ad834bbc027c2ee8f276c58b9dcab0bd343c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764600480,
      "headline": "REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?",
      "id": 137654760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.",
      "url": "https://finnhub.io/api/news?id=047431453b74569e2c937bb7b42ad834bbc027c2ee8f276c58b9dcab0bd343c3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)",
    "summary": "TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical development with Tessera’s pioneering Gene WritingTM and",
    "url": "https://finnhub.io/api/news?id=7a5c4a02b8347f6da801de74668cbdf2f8fa23fc83a52c9860a6dbe5f267083c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764590400,
      "headline": "Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)",
      "id": 137654761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical development with Tessera’s pioneering Gene WritingTM and",
      "url": "https://finnhub.io/api/news?id=7a5c4a02b8347f6da801de74668cbdf2f8fa23fc83a52c9860a6dbe5f267083c"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron inks gene editing deal with startup Tessera",
    "summary": "The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.",
    "url": "https://finnhub.io/api/news?id=fe153ae66296415c70b468f6321e4ccee7b1c21fe38bd4d9dc93370eb6d45d7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764590040,
      "headline": "Regeneron inks gene editing deal with startup Tessera",
      "id": 137654762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a potential one-and-done treatment for alpha-1 antitrypsin deficiency.",
      "url": "https://finnhub.io/api/news?id=fe153ae66296415c70b468f6321e4ccee7b1c21fe38bd4d9dc93370eb6d45d7c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued \"Strong Buy\" Rating",
    "summary": "Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.",
    "url": "https://finnhub.io/api/news?id=cd344b45351b5568fb3d4c58324967399568fd6ee1adbe6e67322c5ec346dc6d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764568505,
      "headline": "AbbVie: Increased Outlook For 2025 And Expansions Merit Continued \"Strong Buy\" Rating",
      "id": 137651736,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247731311/image_2247731311.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Discover why AbbVie (ABBV) is a strong buy with expanding immunology, neuroscience, and oncology pipelines.",
      "url": "https://finnhub.io/api/news?id=cd344b45351b5568fb3d4c58324967399568fd6ee1adbe6e67322c5ec346dc6d"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?",
    "summary": "The comeback may have begun.",
    "url": "https://finnhub.io/api/news?id=dccaf6e6fe626157232603673c8047d606269c9efb83941648e119fad815962a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764562500,
      "headline": "Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?",
      "id": 137650392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The comeback may have begun.",
      "url": "https://finnhub.io/api/news?id=dccaf6e6fe626157232603673c8047d606269c9efb83941648e119fad815962a"
    }
  }
]